https://mindmedicinelaw.com/briefing/belgium-considers-regulated-psychedelic-therapy-access-for-depression-20261016-50705The Psychedelic Journalen2026-10-16T15:05:56.707181+00:00Belgium Considers Regulated Psychedelic Therapy Access for Depressionbelgium psychedelic policy, treatment-resistant depression, psychedelic therapy europe, real-world evidence, clinical access psychedelics, mental health regulation, psilocybin mdma belgium, eu regulatory framework, psychiatric innovationhttps://mindmedicinelaw.com/briefing/defining-psychotherapy-vs-support-in-psychedelic-trials-policy-and-research-impl-20261015-50632The Psychedelic Journalen2026-10-16T15:08:24.186305+00:00Defining Psychotherapy vs. Support in Psychedelic Trials: Policy and Research Implicationspsychedelic clinical trials, psychotherapy definition, psychological support, trial design standards, regulatory approval, reproducibility, cross-study comparison, fda guidance, risk of bias, clinical trial reportinghttps://mindmedicinelaw.com/briefing/global-depression-trends-and-novel-interventions-policy-and-research-context-20261015-50643The Psychedelic Journalen2026-10-16T15:08:01.360220+00:00Global Depression Trends and Novel Interventions: Policy and Research Contextglobal depression trends, ketamine esketamine interventions, digital therapeutics, public health policy, treatment-resistant depression, mental health disparities, neuroinflammation, youth mental health, regulatory frameworkshttps://mindmedicinelaw.com/briefing/colorado-police-raids-highlight-legal-risks-in-psilocybin-and-thc-sales-20261015-50706The Psychedelic Journalen2026-10-16T15:07:04.990279+00:00Colorado Police Raids Highlight Legal Risks in Psilocybin and THC Salescolorado springs, psilocybin law, thc enforcement, police raids, psychedelic policy, natural medicine health act, cannabis regulation, legal risks, market barriershttps://mindmedicinelaw.com/briefing/ethical-lessons-from-psilocybin-therapy-in-advanced-cancer-care-20261015-50633The Psychedelic Journalen2026-10-16T15:06:42.402049+00:00Ethical Lessons from Psilocybin Therapy in Advanced Cancer Carepsilocybin-assisted therapy, advanced cancer, palliative care, informed consent, clinical ethics, aspirational autonomy, oncology, existential outcomes, candidate selection, psychedelic clinical trialshttps://mindmedicinelaw.com/briefing/epa-snurs-under-tsca-impact-on-psychedelic-research-industry-20261015-50220The Psychedelic Journalen2026-10-15T15:08:39.386617+00:00EPA SNURs Under TSCA: Impact on Psychedelic Research & Industryepa snur, tsca, psychedelic research regulation, chemical precursors, compliance risk, novel psychoactive substances, import restrictions, regulatory review, drug development, federal registerhttps://mindmedicinelaw.com/briefing/ayahuasca-regulation-and-ancestral-medicine-in-pastaza-ecuador-20261014-50595The Psychedelic Journalen2026-10-16T15:09:01.696736+00:00Ayahuasca Regulation and Ancestral Medicine in Pastaza, Ecuadorayahuasca regulation, ancestral medicine, ecuador health policy, indigenous rights, pastaza amazon, traditional knowledge protection, intercultural health, public health risks, legal framework, community-driven policyhttps://mindmedicinelaw.com/briefing/ayahuasca-health-risks-consumer-survey-underscores-need-for-regulation-20261014-50596The Psychedelic Journalen2026-10-16T15:08:42.464512+00:00Ayahuasca Health Risks: Consumer Survey Underscores Need for Regulationayahuasca health risks, unsupervised psychedelic use, harm reduction, medical screening, regulatory oversight, consumer survey, traditional vs commercial use, psychedelic policy, mental health effects, indigenous practiceshttps://mindmedicinelaw.com/briefing/ibogaine-s-clinical-promise-and-peril-for-substance-use-disorders-20261014-50598The Psychedelic Journalen2026-10-16T15:07:41.670106+00:00Ibogaine’s Clinical Promise and Peril for Substance Use Disordersibogaine, substance use disorder, psychedelic therapy, clinical trials, cardiotoxicity, noribogaine, regulatory policy, addiction treatment, safety protocolshttps://mindmedicinelaw.com/briefing/blood-brain-barrier-dysfunction-in-trd-new-evidence-for-network-disruption-20261014-50647The Psychedelic Journalen2026-10-16T15:07:23.246285+00:00Blood-Brain Barrier Dysfunction in TRD: New Evidence for Network Disruptionblood-brain barrier, treatment-resistant depression, functional connectivity, psychedelic research, neuroinflammation, default mode network, serotonergic system, clinical trial biomarkers, MRI neuroimaginghttps://mindmedicinelaw.com/briefing/group-psilocybin-retreats-social-connection-findings-and-policy-implications-20261014-50270The Psychedelic Journalen2026-10-15T22:05:07.457881+00:00Group Psilocybin Retreats: Social Connection Findings and Policy Implicationspsilocybin, group therapy, psychedelic retreats, social connectedness, clinical trial design, community mental health, policy implications, observational study, risk assessmenthttps://mindmedicinelaw.com/briefing/active-inference-reality-construction-and-psychopathology-implications-for-psych-20261014-50278The Psychedelic Journalen2026-10-15T22:04:50.105122+00:00Active Inference, Reality Construction, and Psychopathology: Implications for Psychedelic Neuroscienceactive inference, reality construction, psychedelic research, default mode network, psychopathology, clinical trial design, prediction error, social integration, brain oscillations, free energy principlehttps://mindmedicinelaw.com/briefing/group-psilocybin-retreats-social-connection-outcomes-and-policy-implications-20261014-50269The Psychedelic Journalen2026-10-15T15:10:09.843915+00:00Group Psilocybin Retreats: Social Connection Outcomes and Policy Implicationspsilocybin retreat, group psychedelic therapy, social connectedness, clinical trials, psychedelic policy, retreat safety, group facilitation, distress reduction, psychedelic research, community-based carehttps://mindmedicinelaw.com/briefing/participant-advocacy-insights-for-psychedelic-trials-uk-global-policy-implicatio-20261014-50234The Psychedelic Journalen2026-10-15T15:09:47.783659+00:00Participant Advocacy Insights for Psychedelic Trials: UK & Global Policy Implicationspsychedelic clinical trials, participant advocacy, trial design, integration support, psilocybin, dmt, ethics, peer support, regulatory policy, mental health researchhttps://mindmedicinelaw.com/briefing/esketamine-as-adjunct-analgesia-dose-finding-rct-in-chinese-lumbar-surgery-20261014-50272The Psychedelic Journalen2026-10-15T15:09:25.848900+00:00Esketamine as Adjunct Analgesia: Dose-Finding RCT in Chinese Lumbar Surgeryesketamine, opioid-sparing, lumbar decompression surgery, perioperative analgesia, randomized controlled trial, dose finding, patient-controlled intravenous analgesia, sufentanil, multimodal pain management, adverse effectshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-aftercare-standards-gap-in-oregon-colorado-20261014-50273The Psychedelic Journalen2026-10-15T15:09:03.905018+00:00Psilocybin Therapy Aftercare: Standards Gap in Oregon & Coloradopsilocybin therapy, integration, aftercare, oregon psilocybin services, colorado natural medicine act, clinical trial protocols, public health policy, regulatory standards, psychedelic researchhttps://mindmedicinelaw.com/briefing/ai-powered-mapping-of-psychedelic-clinical-trials-global-registry-insights-20261014-50271The Psychedelic Journalen2026-10-15T15:08:13.817185+00:00AI-Powered Mapping of Psychedelic Clinical Trials: Global Registry Insightspsychedelic clinical trials, ai in clinical research, clinicaltrials.gov, psilocybin trials, mdma trials, registry data analysis, trial methodology, global research disparities, systematic review, llm-powered synthesishttps://mindmedicinelaw.com/briefing/neuroplasticity-and-subjective-experience-in-psychedelic-therapy-systematic-revi-20261013-50640The Psychedelic Journalen2026-10-16T15:06:16.761741+00:00Neuroplasticity and Subjective Experience in Psychedelic Therapy: Systematic Review Insights (Global, 2026)psychedelic-assisted psychotherapy, neuroplasticity, subjective experience, clinical trials, policy implications, mechanistic research, depression treatment, hallucinogenic effects, biomarkers, therapeutic protocolshttps://mindmedicinelaw.com/briefing/cortical-criticality-and-arousal-implications-for-psychedelic-neuroscience-20261013-50299The Psychedelic Journalen2026-10-15T22:05:22.243891+00:00Cortical Criticality and Arousal: Implications for Psychedelic Neuroscienceneuronal avalanches, criticality, arousal, cortical networks, psychedelic research, network dynamics, information processing, two-photon imaging, brain entropyhttps://mindmedicinelaw.com/briefing/psilocybin-and-norbaeocystin-acute-anxiety-effects-in-rats-20261013-50236The Psychedelic Journalen2026-10-15T15:11:08.214281+00:00Psilocybin and Norbaeocystin: Acute Anxiety Effects in Ratspsilocybin, norbaeocystin, anxiogenic effects, preclinical study, sex differences, acute adverse effects, clinical trial design, psychedelic safety, rodent modelshttps://mindmedicinelaw.com/briefing/ai-driven-pharmacovigilance-for-neuropsychiatric-drugs-fda-prospects-and-pitfall-20261013-50238The Psychedelic Journalen2026-10-15T15:10:52.266239+00:00AI-Driven Pharmacovigilance for Neuropsychiatric Drugs: FDA Prospects and Pitfallsai pharmacovigilance, fda drug safety, neuropsychiatric drugs, esketamine surveillance, psychedelic therapies, adverse event detection, natural language processing, regulatory decision-making, risk mitigation, real-world evidencehttps://mindmedicinelaw.com/briefing/intranasal-esketamine-for-treatment-resistant-depression-evidence-and-policy-imp-20261013-50282The Psychedelic Journalen2026-10-15T15:10:32.393754+00:00Intranasal Esketamine for Treatment-Resistant Depression: Evidence and Policy Implicationsesketamine, treatment-resistant depression, acute suicidality, intranasal administration, clinical trials, NMDA antagonist, psychiatric emergency care, adverse effects, policy implications, maintenance therapyhttps://mindmedicinelaw.com/briefing/rtms-response-varies-by-depressive-phenotype-preclinical-insights-20261013-50094The Psychedelic Journalen2026-10-14T22:07:25.644610+00:00rTMS Response Varies by Depressive Phenotype: Preclinical InsightsrTMS, treatment-resistant depression, phenotype-specific response, neuroendocrine markers, Bdnf, Cnr1, preclinical depression models, personalized neuromodulation, psychedelic research, biomarker-guided trialshttps://mindmedicinelaw.com/briefing/psychedelic-induced-personality-changes-evidence-and-gaps-global-2014-2024-20261013-50054The Psychedelic Journalen2026-10-14T22:06:37.426471+00:00Psychedelic-Induced Personality Changes: Evidence and Gaps (Global, 2014–2024)psychedelic research, personality trait change, neuroticism, systematic review, clinical trial design, regulatory considerations, mental health, psilocybin, LSD, ayahuascahttps://mindmedicinelaw.com/briefing/ketamine-for-trd-efficacy-differs-by-depression-subtype-and-trauma-20261013-50095The Psychedelic Journalen2026-10-14T22:06:15.711177+00:00Ketamine for TRD: Efficacy Differs by Depression Subtype and Traumaketamine, treatment-resistant depression, melancholic depression, depressive subtypes, childhood trauma, psychedelic-assisted therapy, clinical trials, precision psychiatry, biomedical ketamine, regulatory policyhttps://mindmedicinelaw.com/briefing/multimodal-imaging-validates-plasticity-markers-after-dmt-ketamine-in-uk-study-20261013-50112The Psychedelic Journalen2026-10-14T22:05:56.426871+00:00Multimodal Imaging Validates Plasticity Markers After DMT, Ketamine in UK Studysynaptic plasticity, pet imaging, dmt, ketamine, neuroimaging biomarkers, clinical trial endpoints, sv2a, diffusion weighted imaging, eeg, psychedelic researchhttps://mindmedicinelaw.com/briefing/peyote-ho-chunk-healing-and-policy-indigenous-use-and-regulatory-debate-20261012-50087The Psychedelic Journalen2026-10-15T22:05:38.345574+00:00Peyote, Ho-Chunk Healing, and Policy: Indigenous Use and Regulatory Debatepeyote, ho-chunk nation, native american church, indigenous healing, trauma recovery, psychedelic regulation, religious freedom, cultural preservation, public health ethicshttps://mindmedicinelaw.com/briefing/acute-basolateral-amygdala-dbs-shows-no-behavioral-impact-in-rats-20261012-50098The Psychedelic Journalen2026-10-14T22:09:19.779757+00:00Acute Basolateral Amygdala DBS Shows No Behavioral Impact in Ratsdeep brain stimulation, basolateral amygdala, preclinical safety, psychiatric neuromodulation, anxiety behavior, fear memory, rat models, translational research, psychedelic research, regulatory sciencehttps://mindmedicinelaw.com/briefing/oral-ketamine-assisted-psychotherapy-in-dnsd-case-report-and-clinical-implicatio-20261012-50100The Psychedelic Journalen2026-10-14T22:08:54.295379+00:00Oral Ketamine-Assisted Psychotherapy in DNSD: Case Report and Clinical Implicationsketamine-assisted psychotherapy, dissociative neurological symptom disorder, functional neurological disorder, case report, oral ketamine, mutism, treatment-resistant, psychedelic research, clinical evidence, off-label usehttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-in-ukraine-evidence-gaps-and-future-directions-20261012-50057The Psychedelic Journalen2026-10-14T22:08:36.319782+00:00Psychedelic-Assisted Therapy in Ukraine: Evidence, Gaps, and Future Directionspsychedelic-assisted therapy, psilocybin, mdma, lsd, ayahuasca, ukraine, clinical trials, mental health, policy, evidence gapshttps://mindmedicinelaw.com/briefing/standardizing-visual-snow-syndrome-diagnosis-implications-for-psychedelic-resear-20261012-50086The Psychedelic Journalen2026-10-14T22:08:14.259028+00:00Standardizing Visual Snow Syndrome Diagnosis: Implications for Psychedelic Researchvisual snow syndrome, diagnostic protocol, psychedelic research, adverse event monitoring, hallucinogen persisting perception disorder, cortical hyperexcitability, biomarker development, clinical trials, neurological safety, regulatory policyhttps://mindmedicinelaw.com/briefing/suzetrigine-analgesia-enhanced-by-nav1-7-null-opioid-mechanisms-preclinical-insi-20261012-50099The Psychedelic Journalen2026-10-14T22:07:51.743047+00:00Suzetrigine Analgesia Enhanced by Nav1.7 Null Opioid Mechanisms: Preclinical Insightssuzetrigine, nav1.7 sodium channel, endogenous opioid signaling, analgesia, pain management, preclinical research, rgs antagonists, inflammatory pain, clinical translationhttps://mindmedicinelaw.com/briefing/low-dose-esketamine-in-emergency-c-sections-rct-evidence-from-china-20261012-50097The Psychedelic Journalen2026-10-14T22:07:02.588531+00:00Low-Dose Esketamine in Emergency C-Sections: RCT Evidence from Chinaesketamine, emergency cesarean section, labor analgesia, randomized controlled trial, maternal hemodynamics, neonatal outcomes, acute pain management, obstetric anesthesia, clinical safetyhttps://mindmedicinelaw.com/briefing/psilocybin-assisted-mbsr-in-healthcare-workers-rct-mechanisms-and-policy-outlook-20261011-50244The Psychedelic Journalen2026-10-15T15:11:22.704436+00:00Psilocybin-Assisted MBSR in Healthcare Workers: RCT Mechanisms and Policy Outlookpsilocybin, mindfulness-based stress reduction, mystical experience, healthcare workers, depression, randomized controlled trial, mechanism of action, psychedelic-assisted therapy, clinical research, policy implicationshttps://mindmedicinelaw.com/briefing/rct-online-family-intervention-reduces-drug-initiation-in-hispanic-youth-us-prim-20261009-50063The Psychedelic Journalen2026-10-15T22:05:54.126292+00:00RCT: Online Family Intervention Reduces Drug Initiation in Hispanic Youth (US Primary Care)e-health intervention, hispanic adolescents, primary care prevention, drug initiation, psychedelic use, family-based intervention, public health policy, clinical trial, cultural tailoringhttps://mindmedicinelaw.com/briefing/circadian-timing-modulates-antidepressant-pathways-in-mouse-brain-20261008-50251The Psychedelic Journalen2026-10-15T22:06:13.047121+00:00Circadian Timing Modulates Antidepressant Pathways in Mouse Braincircadian rhythms, antidepressant pathways, psychedelic trials, preclinical research, molecular neuroscience, trial design, translational medicine, time-of-day effects, TrkB signaling, clinical implicationshttps://mindmedicinelaw.com/briefing/psychedelic-assisted-psychotherapy-evidence-review-and-policy-outlook-global-202-20261001-50354The Psychedelic Journalen2026-10-15T22:06:30.235270+00:00Psychedelic-Assisted Psychotherapy: Evidence Review and Policy Outlook (Global, 2026)psychedelic-assisted psychotherapy, clinical trial evidence, policy implications, integration protocols, regulatory pathways, safety considerations, FDA breakthrough therapy, public health, therapist training, long-term outcomes